Stemline Therapeutics

Stemline Therapeutics was a biopharmaceutical company focused on developing treatments for oncology. The company was acquired by Menarini Group in 2021. Stemline's pipeline included treatments for hematologic malignancies and solid tumors.

Source: https://www.menarini.com

elacestrantOrserdu

selective estrogen receptor degrader (SERD)

Orserdu (elacestrant) is an oral selective estrogen receptor degrader from Stemline. It binds the estrogen receptor and marks it for destruction, and is used in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation after prior endocrine therapy.

ER-positive breast cancers grow in response to estrogen acting on the estrogen receptor. After treatment with standard hormone therapies, cancers ofte

1 medicine explained